

REFERENCE

- Akdede, B.B.K. 2005. Effects of quetiapine on cognitive functions in schizophrenia. *Journal of Progress in Neuro-Psychopharmacology & Biological Psychiatry*; 29: 233– 238.
- Arvanitis, L.A., and Miller, B.G. 1997. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. *Journal of Biological Psychiatry*; 42(4): 233-246.
- AstraZeneca. 2006. *Product monograph : Seroquel®*.
- Aulton, M.E. 2002. *Pharmaceutics: the science of dosage form design*. 2nd ed. Churchill Livingstone. USA. pp. 66-70.
- Avenoso, A., Facciola, G., Salemi, M., and Spina, E. 2000. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. *Journal of Chromatography B*; 746: 173-181.
- Barrett, B., Holcapek, M., Huclova, J., *et al.* 2007. Validated HPLC-MS/MS method for determination of quetiapine in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*; 44: 498-505.
- Benet, L.Z. 1999. Understanding bioequivalence testing. *Journal of Transplantation Proceedings*; 31(Suppl 3A): 7S-9S.
- Borison, R.L., Arvanitis, L.A., and Miller, B.G. 1996. ICI 204,636, an atypical antipsychotic efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. *Journal of Clinical Psychopharmacology*; 16(2): 158-169.
- Bowden, C.L., Grunze, H., Mullen, J., *et al.* 2005. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. *Journal of Clinical Psychiatry*; 66: 111–121.
- Buckley, P.F., Paulsson, B., and Brecher, M. 2007. Treatment of agitation and aggression in bipolar mania: Efficacy of quetiapine. *Journal of Affective Disorder*; 19: 82-96.

- Burton, M.E., Shaw, L.M., Schentag, J.J., and Evans, W.E. 2006. *Applied Pharmacokinetics & Pharmacodynamics*. 4th ed. Lippincott Williams & Wilkins. USA. pp. 260-277.
- Calabrese, J.R., Keck, J.R., Macfadden, W., *et al.* 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *American Journal of Psychiatry*; 162: 1351-1360.
- Catalano, G., Catalano, M.C., Agustines, RE., Dolan, EM., and Paperwalla, KN. 2002. Pediatric quetiapine overdose: a case report and literature review. *Journal of Child and Adolescent Psychopharmacology*; 12(4): 355-361.
- Chen, ML., Shan, V., Patnaik, R., *et al.* 2001. Bioavailability and bioequivalence: a FDA regulatory overview. *Journal of Pharmaceutical Research*; 18(12): 1645-1650.
- Committee for Proprietary Medicinal Products (CPMP), Working Party on Efficacy of Medicinal Products. Note for guidance: Investigation of bioavailability and bioequivalence 1998. *Journal of Psychopharmacology*; 135: 119-126.
- Conley, R.R., and Kelly, D.L. 2004. Long-term efficacy, effectiveness and safety of atypical antipsychotic drugs. In: Csernansky, J.G. and Lauriello, J. (eds). *Atypical antipsychotic from bench to bedside*. Marcel Dekker, Inc. New York. pp. 198.
- Conley, R.R., and Kelly, D.L. 2007. Drug-drug interactions associated with second generation antipsychotics: considerations for clinicians and patients. *Journal of Psychopharmacology Bulletin*; 40(1): 77-98.
- Copolov, D.L., Link, C.G., and Kowalczyk, B. 2000. A multicenter, double-blind, randomized comparison of quetiapine (ICI 204,636 "Seroquel") and haloperidol in schizophrenia. *Journal of Psychological Medicine*; 30(1): 95-105.
- Crismon, M.L. and Dorson, P.G. 2002. Schizophrenia. In: DiPiro, J.T., Talbert, R.L., Yee, G.C., *et al* (eds). *Pharmacotherapy: a pathophysiologic approach*. 5th ed. McGraw-Hill. New York. pp. 1219-1223.
- Cutler, A.J, Goldstein, J.M., and Tumas, J.A. 2002. Dosing and switching strategies for quetiapine fumarate. *Journal of Clinical Therapeutics*; 24 (2): 210-222.

- Dando, T.M., and Keating, G.M. 2005. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. *Journal of Drugs*; 65(17): 2533-2551.
- Danielson, P.B. 2003. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. *Journal of Current Drug Metabolism*; 3: 561-597.
- Dargham, A., and Laruelle, M. 2005. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. *European Journal of Psychiatry*; 20: 15-27.
- Davis, P.C., Wong, J., and Gefvert, O. 1999. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reverse-phase HPLC with ultraviolet and electrochemical detection. *Journal of Pharmaceutical and Biomedical Analysis*; 20: 271-282.
- DeVane, C.L., and Nemeroff, C.B. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. *Journal of Clinical Pharmacokinetics*; 40(7): 509-522.
- Doree, J.P., Des Rosiers, J., Lew, V., *et al.* 2007. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. *Journal of Current Medical Research and Opinion*; 23(2): 333-341.
- Ebert, M.H., Lousen, P.T. and Nurcombe, B. 2000. *Current diagnosis & treatment in psychiatry*. McGraw-Hill. New York. pp. 260-277.
- Emsley, R.A., Raniwalla, J., Bailey, P.J., *et al.* 2000. A comparison of the effects of quetiapine (“Seroquel”) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. *International Journal of Clinical Psychopharmacology*; 15(3): 121-131.
- Endrenyi, L., and Midha, K.K. 1998. Individual bioequivalence-has its time come?. *European Journal of Pharmaceutical Sciences*; 6: 271–277.
- Flagstad, P., Arnt, J., and Olsen, C.K. 2006. Classical as well as novel antipsychotic drugs increase self-stimulation threshold in the rat - similar mechanism of action. *European Journal of Pharmacology*; 544: 69–76.

- Flischhacker, W.W., Link, C.G.G., and Hurst, B.C. 1996. ICI 204,636 (Seroquel). A putative new atypical antipsychotic: results from phase III trials. *Journal of Schizophrenia Research*; 18(2): 132-132.
- Friedericy, H.J., and Bovill, J.G. 1998. The role of the cytochrome P450 system in drug interactions in anaesthesia. *Journal of Bailliere's Clinical Anaesthesiology*; 12(2): 213- 228.
- Gaete, L.E., Solis, J., Venegas, P., Carrillo, M.J., Schatloff, O., and Saavedra, I. 2003. Comparative bioavailability study of two formulations of risperidone available in the Chilean market. *Journal of Revista Medica de Chile*; 131(5): 527-534.
- Gefvert, O., Bergstrom, M., Langstrom, B., Lundberg, T., Lindstrom, L., and Yates, R. 1998. Time course of central nervous dopamine-D₂ and 5-HT₂ receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. *Journal of Psychopharmacology (Berl)*; 135: 119-126.
- Gelder, M., Mayou, R., and Geddes, J. 1999. *Psychiatry*. 2nd ed. Oxford University Press, Oxford. pp.158-162.
- Glick, I.D., and Marder, S.R. 2005. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. *Journal of Clinical Psychiatry*; 66(5): 638-641.
- Goldman, H.H. 2000. *Review of general psychiatry*. 5th ed. McGraw- Hill. New York. pp. 233-249.
- Goren, J.L., and Levin, G.M. 1998. Quetiapine, an atypical antipsychotic. *Journal of Pharmacotherapy*; 18(6): 1183-1194.
- Gram, T.E. 1997. Metabolism of drugs. In: Craig, C.R. and Stitzel, R.E. (eds). *Modern pharmacology with clinical applications*. 5th ed. Little Brown, USA. pp. 25-30.
- Granero, G.E., and Amidon, G.L. 2007. Possibility of enterohepatic recycling of ketoprofen in dogs. *International Journal of pharmaceutics*; xxx: xxx-xxx.
- Grimm, S.W., Stams, K.R. and Bui, K. 1997. In vitro prediction of potential metabolic drug interaction for Seroquel. *Journal of Schizophrenia Research*; 24(2): 198.

- Grimm, S.W., Richtand, N.M., Winter, H.R., Stams, K.R., and Reece, S.B. 2005. Effects of cytochrome P450 3A modulators: ketoconazole and carbamazepine on quetiapine pharmacokinetics. *British Journal of Clinical Pharmacology*; 61(1): 58-69.
- Hales, R.E., and Yudofsky, S.C. 2004. *Essentials of clinical psychiatry*. 2nded. American Psychiatrc publishing. Inc. Washington DC. pp. 842-843.
- Hasselstrom, J., and Linnet, K. 2006. In vitro studied on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interaction. *Journal of Drug Metabolism and Drug Interactions*; 21(3-4): 187-211.
- Heinz, A. 2002. Dopaminergic dysfunction in alcoholism and schizophrenia - psychopathological and behavioral correlates. *European Journal of Psychiatry*; 17(1): 9-16.
- Hendrickson, R. 2006. *Remington: The science and practice of pharmacy*. 21th ed. Lippincott.Williams & Wilkins. Philadelphia. pp. 1037-1046.
- Hunfeld, N.G., Westerman, E.M., Boswijk, D.J., Haas, J.A. Putten, M.J., and Touw, D.J. 2006. Quetiapine in overdose: a clinical and pharmacokinetic analysis of 14 cases. *Journal of Therapeutic Drug Monitoring*; 28(2): 185-189.
- Jablensky, A. 1997. The 100-year epidemiology of schizophrenia. *Journal of Schizophrenia Research*; 28: 111-125.
- Jaskiw, G.E., Thyrum, P.T., Fuller, M.A., Arvanitis, L.A., and Yeh, C. 2004. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. *Journal of Clinical Pharmacokinetics*; 43(14): 1025-1035.
- Judit, N. 2005. Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up. *International Journal of Psychiatry in Clinical Practice*; 9(1): 16-21.
- Kapur, S., Zipursky, R., Jones, C., Shammi, C.S., Remington, G., and Seeman, P. 2000. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. *Journal of Archives of General Psychiatry*; 57: 553– 559.
- Kashuba, A.D.M., Park, J.J., Persky, A.M., and Brouwer, K.L.R. 2006. Drug metabolism, treatment, and the influence of hepatic disease. In: Burton, M.E.,

- Shaw, L.M., Schentag, J.J., and Evans, W.E (eds). *Applied Pharmacokinetics & Pharmacodynamics: Principles of therapeutic drug monitoring*. 4th ed. Lippincott Williams & Wilkins. USA. pp. 145-150
- Kasper, S., Brecher, M., Filton, L. *et al.* 2004. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. *International Journal of Clinical Psychopharmacology*, 19 (5): 281-289.
- Katzung, B.G. 2001. *Basic & clinical pharmacology*. 8th ed. McGraw-hill. USA. pp. 53.
- Kay, J., Tasman, A., and Lieberman, J.A. 2000. *Psychiatry*. W.B. Saunders Company. Philadelphia. pp. 312-321.
- Khazaal, Y., Tapparell, S., Chatton, A., Rothen, S., Preisig, M., and Zullino, D. 2007. Quetiapine dosage in bipolar disorder episodes and mixed states. *Progress in Neuro-psychopharmacology and Biological Psychiatry*; 31(3): 727-730.
- King, D.J. 1998. Quetiapine: results of four phase II and III clinical trials. *European Journal of Psychiatry*; 13(1): 15-21.
- King, D.J., Link, C.G.G., and Kowalczyk, B. 1998. A comparison of bid and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. *Journal of Psychopharmacology*; 137: 13-146.
- Koda-Kimble, M.A., Young, L.Y., Kradjan, W.A., and Guglielmo, B.J. 2001. *Applied therapeutics: The clinical use of drugs*. Lippincott Williams & Wilkins. USA. pp. 76.
- Kongsakon, R., Leelahanaj, T., Price, N., Birinyi-Strachan, L., and Davey, P. 2005. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. *Journal of the Medical Association of Thailand*; 88(9): 1267-1277.
- Kurth, J., and Maguire, G. 2004. Pediatric case report of quetiapine overdose and QTc prolongation. *Journal of Annals of Clinical Psychiatry*; 16(4): 229-231.
- Kytariolos, J., Karalis, V., Macheras, P., and Symillides, M. 2006. Novel scaled bioequivalence limits with leveling-off properties. *Journal of Pharmaceutical Research*; 23(11): 2657-2664.

- Lam, Y.W., Ereshefsky, L., Toney, G.B., and Gonzales, C. 2001. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. *Journal of Clinical Psychiatry*; 62(5): 18-22.
- Leon, J., Armstrong, SC., and Cozza, KL. 2005. The dosing of atypical antipsychotics. *Journal of Psychosomatics*; 46 (3): 262-273.
- Li K.Y, Li X., Cheng Z.N, Peng W.X., Zhang B.K., and Li H.D. 2004. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. *Journal of Acta Pharmacologica Sinica*; 25(3): 390-394.
- Li K.Y., Li X., Cheng Z.N, Peng W.X, Zhang B.K., and Li H.D. 2005. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. *European Journal of Clinical Pharmacology*; 60: 791-795.
- Lieberman, J.A., Mailman, R.B., Duncan, G., *et al.* 1998. Serotonergic basis of antipsychotic drug effects in schizophrenia. *Journal of Biological Psychiatry*; 44: 1099-1117.
- Liu, J., and Chow, S.C. 1992. Sample size determination for the two one-sided test procedures in bioequivalence. *Journal of Pharmacokinetics and Biopharmaceutics*; 20(1): 101-104.
- Li W.B., Chuan-yue, W., Yi-in, Z., *et al.* 2006. Pharmacokinetics and bioequivalence of domestic and imported olanzapine tablets in healthy volunteers. *Chinese Journal of New Drug*; 14(5): 599-602.
- Mandrioli, R., Fanali, S., Ferranti, A., and Raggi, M.A. 2002. HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*; 30 (2002): 969-977.
- Marzo, A., Monti, N.C., and Vuksic, D. 1999. Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials. *European Journal of Clinical Pharmacology*; 55: 627-631.
- McIntyre, R.S., Brecher, M., Paulsson, B., Huizar, K., and Mullen J. 2005. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo controlled trial. *European Journal of Neuropsychopharmacology*; 15: 573-85.

- Midha, K.K., Chakraborty, B.S., Schwede, R., Hawes, E.M., Hubbard, J.W., and McKay, G. 1989. Comparative bioavailability of a new commercial tablet formulation and two lots of a reference formulation of haloperidol. *Journal of Pharmaceutical Science*; 78(6): 443-447.
- Moller, H.J. 2005. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?. *European Journal of Archive Psychiatry Clinical Neuroscience*; 255: 190-201.
- Moor, D.P., and Jefferson, J.W. 2004. *Handbook of medical psychiatry*. 2nd ed. Lippincott William & Wilkins, USA. pp.487.
- Mueser, K.T., and McGurk, S.R. 2004. Schizophrenia. *The Lancet* ; 363: 2063-2072.
- Mullen, J., Jibson, M.D., and Sweitzer, D. 2001. A comparison of the relative safety, efficacy and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorder: the quetiapine experience with safety and tolerability (QUEST) study. *Journal of Clinical Therapy*; 23(11): 1839-1854.
- Na Bangchang, K., and Wernsdorfer, W.H. 2001. *Fundamental clinical pharmacokinetics*. Thammasat University, Thailand. pp. 29-107.
- Nasrallah, H. 2003. A review of the effect of atypical antipsychotics on weight. *Journal of Psychoneuroendocrinology*; 28: 83-96.
- Nebert, D.W., and Russell, D.W. 2002. Clinical importance of the cytochromes P450. *The Lancet*; 360: 1155-1162.
- Onor, M.L., Saina, M., and Aguglia, E. 2007. Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. *American Journal of Alzheimer's Disease and Other Dementias*; 21(6): 448-453.
- Otyepka, M., Skopalik, J., Anzenbacherova, E., *et al.* 2007. What common structural features and variations of mammalian P450s are known to date?. *Journal of Biochimica et Biophysica Acta*; 1770: 376-389.
- Pais, V.M., and Ayvazian, P.J. 2001. Priapism from quetiapine overdose: first report and proposal of mechanism. *Journal of Urology*; 58(3): 462.
- Palmer, A. 2005. Drug review-quetiapine. *Journal of Drug in Context*; 1(13): 691-715.

- Parker, D.R., and McIntyre, I.M. 2005. Case report: case studies of postmortem quetiapine: therapeutic or toxic concentration. *Journal of Analytical Toxicology*; 29(5): 407-412.
- Petty, R.G. 1999. Prolactin and antipsychotic medications: mechanism of action. *Journal of Schizophrenia Research*; 35: S67-S73.
- Pini, S., Abelli, M., and Cassano, G.B. 2006. The role of quetiapine in the treatment of bipolar disorder. *Journal of Expert Opinion on Pharmacotherapy*; 7(7): 929-940.
- Potkin, S.G., Thyrum, P.T., Alva, G. *et al.* 2002. Effects of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. *Journal of Clinical Psychopharmacology*; 22(2): 174-283.
- Prior, T.I., Chue, P.S., Tibbo, P., and Baker, G.B. 1999. Drug metabolism and atypical antipsychotics. *European Journal of Neuropsychopharmacology*; 9: 301-309.
- Rahi, M., Heikkinen, T., Hartter, S. *et al.* 2007. Placental transfer of quetiapine in relation to P-glycoprotein activity. *Journal of Psychopharmacology*; 26: 45-50.
- Rani, S., and Pargal, A. 2004. Bioequivalence: an overview of statistical concepts. *Indian Journal of Pharmacology*; 36(4): 209-216.
- Rowland, M., and Tozer, T.N. 1995. *Clinical pharmacokinetics: concepts and applications*. 3rd ed. Williams & Wilkins. USA. pp. 208-210.
- Sachs G., Chengappa K.N., Suppes T. *et al.* 2004. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo controlled study. *Journal of Bipolar Disorder*; 6: 213–23.
- Sachse, J., Koller, J., Hartter, S., and Hiemke, C. 2006. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance liquid chromatography with column-switching and spectrophotometric detection. *Journal of Chromatography B*. 830: 342-348.
- Sadock, B.J., and Sadock V.A. 2001. *Pocket handbook of psychiatric drug treatment*. 3rd ed. Lippincott Williams & Wilkins, Philadelphia. USA. pp. 206.
- Saracino, M.A., Mercolini, L., Flotta, G., Albers, L.J., Merli, R., and Raggi, M.A. 2006. Simultaneous determination of fluvoxamine isomers and quetiapine in

- human plasma by means of high performance liquid chromatography. *Journal of Chromatography B*; 843(2): 227-233.
- Schaick, E.A., Lechat, P., Remmerie, B.M., Ko, G., Lasseter, K.C., and Mannaert, E. 2003. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. *Journal of Clinical Therapy*; 25(6): 1687-1699.
- Schatzberg, A.F., Cole, O.J., and DeBattista C. 2005. *Manual of clinical psychopharmacology*. 5th ed. American Psychiatric Publishing Inc., Washington DC. pp. 193-197.
- Schatzberg, A.F., and Nemeroff, C.B. 2001. *Essentials of clinical psychopharmacology*. American Psychiatry publishing. Inc., Washington DC. pp. 145-150
- Seeman, P. 2002. Atypical antipsychotics: mechanism of action. *Canadian Journal of Psychiatry*; 47(1): 27-38.
- Sharif, Z.A. 2003. Pharmacokinetics, metabolism and drug-drug interactions of atypical antipsychotics in special populations. *Journal of Clinical Psychiatry*; 5(6): 22-25.
- Shargel, L., and Yu, A. 1999. *Applied biopharmaceutics & pharmacokinetics*. 4th ed. McGraw-Hill, USA. pp. 247-271.
- Shargel, L., Wu-Pong, S., and Yu, A. 2005. *Applied biopharmaceutics & pharmacokinetics*. 5th ed. McGraw-Hill, USA. pp. 395-396.
- Singh S.S, and Sharma K. 2005. Validation of LC-MS electrospray ionisation method for quantitation of haloperidol in human plasma and its application to bioequivalence study. *Journal of Analytica Chimica Acta*; 551: 159–167.
- Siriwanarangsun, P., Kongsuk, T., Arunpongpaisan, S., Kittirattanapaiboon, P., and Charatsingha, A. 2003. Prevalence of mental disorders in Thailand: a national survey 2003. *Journal of Mental Health of Thailand*; 12 (3): 177-188.
- Small, J.G., Arvanitis, L.A., Hirsch, S.R. et al. 1997. Quetiapine in patients with schizophrenia, a high and low dose double-blind comparison with placebo. Seroquel Study Group. *Journal of Archives of General Psychiatry*; 54(6): 549-557.

- Stahl, S.M. 2000. *Essential psychopharmacology: Neuroscientific basis and practical applications*. 2nd ed. Cambridge University Press, USA. pp. 375-380.
- Stahl, S.M. 2003. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. *Primary Care Companion Journal of Clinical Psychiatry*; 5 (suppl 3): 9-13.
- Stevens, J.R., Kymissis, P.I., and Baker, A.J. 2005. Elevated prolactin levels in male youths treated with risperidone and quetiapine. *Journal of Child and Adolescent Psychopharmacology*; 15(6): 893-900.
- Strakowski, S.M., Keck, P.E., Wong, Y.W. *et al.* 2002. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in man with selected psychotic disorders. *Journal of Clinical Psychopharmacology*; 22(2): 201-205.
- Taesotikul, W., Kaewvichit, S., Wongsinsup, C., Sornsuvit, C., Sanichwankul, K., and Pumpaisachai, W. 2000. Bioequivalence of clozapine tablets. *Journal of Psychiatry Association of Thailand*; 45(3): 221-226.
- Tantivess, S., Jierapong, S., Jitraknatee, A., and Chakajnarodom, S. 2002. Generic entry and drug expenditures of hospitals: case study of drugs approved by means of the new drug registration regulations. *Journal of Health Science*. 11(2): 167-176.
- Tandom, V. 2002. Bioavailability and bioequivalence. In: Schoenwald, R.D. (ed). CRC Press, USA. pp. 95-105.
- Tariot, P.N., Salzman, C., Yeung, P.P. *et al.* 2000. Long-term use of quetiapine in elderly patients with psychotic disorders. *Journal of Clinical Therapy*; 22 (9): 1068-1084.
- Tassaneeyakul, W., Kittiwattanagul, K., Vannaprasaht, S. *et al.* 2005. Steady-state bioequivalence study of clozapine tablet in schizophrenic patients. *Journal of Pharmacokinetics and Pharmaceutical Science*; 8(1): 47-53.
- Thai Food and Drug Administration (FDA). 2006. Criteria and guideline for the bioequivalence study of generic drug.
- Thomson, A. 2004. Back to basics: pharmacokinetics. *The pharmaceutical Journal*; 272: 769-771.

- Thyrum, P.T., Wong, Y.J., and Yes, C. 2000. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. *Progress in Neuro-psychopharmacol & Biological Psychiatry*; 24: 521-533.
- Timothy, P., and Kevin, Z. 2000. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. *Journal of Clinical Pharmacology Therapy*; 68: 92-97.
- Tomb, D.A. 1999. *Psychiatry*. 6th ed. Lippincott William & Wilkins. USA. pp. 21-30.
- Toutain, P.L., and Koritz, G.D. 1997. Veterinary drug bioequivalence determination. *Veterinary Journal of Pharmacology Therapy*; 20: 79-90.
- Weringh, G., Komen, B.J., Thieme, R.E., Hoeven, R.T., and Vos, T. 1994. Comparative bioavailability study of two haloperidol decanoate containing products. *Journal of Pharmacy World and Science*; 16(6): 243-247.
- Westlake, W.J. 1979. Statistical aspects of comparative bioavailability trials. *Journal of Biometrics*; 35: 273-280.
- Wong Y.W., Yeh, C., and Thyrum, P.T. 2001. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. *Journal of Clinical Psychopharmacology*; 21(1): 89-93.
- Wrighton, S.A., and Thummel, K.E. 2000. CYP3A. In: Levy, R.H., Thummel, K.E., Trager, W.F., Hansten, *et al* (eds). *Metabolic drug interactions*. Lippincott Williams & Wilkins. Philadelphia. USA. pp. 230-252.
- Yengi, L.G., Leung, L. and Kao, J. 2006. The evolving role of drug metabolism in drug discovery and development. *Journal of Pharmaceutical Research*; 24(5): 842-858.
- Yun, M.H., Kwon, J.T., and Kwon, K.I. 2005. Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. *Journal of Archives of Pharmacal Research*; 28(4): 488-492.
- Zhong, K.X., Sweitzer, D.E., Hamer, R.M., and Lieberman, J.A. 2006. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double blind, flexible-dose, 8-week study. *Journal of Clinical Psychiatry*; 67(7): 1093-1103.

Zhou, S., Chan, E., Lim, L.Y. *et al.* 2004. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. *Journal of Current Drug Metabolism*; 5: 415-442.